The use of MDM2 inhibitors in cancer types with low p53 mutation frequencies, such as thyroid carcinoma, acute myeloid leukaemia (AML), melanoma and others (Fig. 2), gave hope for this approach to be widely used in cancer treatment. Here, MDM2 is linked to acute myeloid leukemia.